Seattle Genetics reported earnings on Tuesday. Despite the solid growth in sales, shares opened down today, possibly due to conservative guidance for the year ahead. Adcetris sales in the U.S. and ...

Drug development partner Takeda is paying Seattle Genetics $20 million because of sales of its lymphoma drug Adcetris. © 2025 American City Business Journals. All ...

What: Shares of Seattle Genetics, a biotechnology company developing targeted cancer therapies, gained 9.83% in March, according to data from S&P Global Market Intelligence. The news flow last month ...